Late-stage results indicate that Cytokinetics' heart drug can compete with a similar treatment sold by Bristol Myers Squibb in terms of efficacy and safety. Despite facing pressure to sell to a larger pharmaceutical company, Cytokinetics CEO Robert Blum maintains that the biotech firm can launch the heart drug on its own. This statement was reiterated during a fireside chat at STAT's Breakthrough Summit West, where Blum addressed acquisition speculation.
Amid acquisition speculation, Cytokinetics CEO stresses company can launch heart drug on its own https://t.co/NdFRZt8ljl via @elaineywchen for @statnews
As Cytokinetics faces pressure to sell to a large pharma company, CEO Robert Blum maintains that the biotech can launch its heart drug on its own. #STATBreakthrough https://t.co/WAX3zH37Xb
I had a great on-stage chat with $CYTK CEO Robert Blum y'day at the STAT Summit. At one point, his cell phone rang. I thought, maybe it's Novartis calling! My colleague @elaineywchen write-up of the conversation: Amid acquisition speculation, Cytokinetics CEO stresses company…
Cytokinetics CEO stresses company can launch heart drug on its own #statbreakthrough https://t.co/ITuj0qwj3m
I'm on my way to SF for STAT's Breakthrough Summit West. Currently 34K feet over Iowa. I can see Caitlin Clark from here! Tomorrow at 4:30 pm PT, I will be "fireside chatting" with $CYTK CEO Robert Blum. I have a long list of questions and topics but I welcome more from you.…
Results of Cytokinetics’ drug for a rare heart disease suggest it can compete with a similar treatment sold by Bristol Myers Squibb on efficacy and safety. https://t.co/HSt7NuCzQZ
Late-stage results set up Cytokinetics heart drug to compete with Bristol https://t.co/0WMtcqHBYG via @statnews
Late-stage results set up Cytokinetics heart drug to compete with Bristol https://t.co/O9dAnMuEZ1 via @elaineywchen for @statnews